/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
$13.07
+$0.20 (+1.55%)
EOD Sep 18, 2026
ROIC dropped from -43.86% to -65.67%, capital efficiency is deteriorating. Negative free cash flow of -$285M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$297M
▼ -26.9% YoY
Op. Margin
—
ROIC
-83.86%
▼ -21.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$281M
▼ -43.0% YoY
Op. Cash Flow (TTM)
-$279M
▼ -45.8% YoY
Net Debt
-$83M
Net Cash Position
Cash & Equiv.
$195M
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 19 Sept 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Mar. Sector medians are approximate S&P 500 benchmarks and update periodically.